FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Travere Therapeutics, Inc. [TVTX]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>Dube Eric M</u>				-	Travere Therapeuties, me. [1 v 1 x]							V Director	,	10% Owner		ner	
(Last)	(F	irst)	(Middle)	 	. Date o	of Earliest	Trans	saction (Mor	nth/D	ay/Year)			Officer (below)	(give title		Other (sp below)	ecify
C/O TRAVERE THERAPEUTICS, INC.				0	01/21/2021						Chief Executive Officer						
3611 VALLEY CENTRE DR., SUITE 300																	
					4. If Amendment, Date of Original Filed (Month/Day/Year) 01/25/2021						6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SAN DII	EGO C.	۸	92130	ا	1/25/2	2021						- 1	,	ed by One I	Reportin	ng Person	
,———	EGO C.	A	92130										Form fil Person	ed by More	than Or	ne Reporti	ng
(City)	(S	tate)	(Zip)										1 613011				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				ite	Execution Date,		Code (Instr.				5. Amoun Securities Beneficia Owned Fo	s lly ollowing	6. Owner Form: Di (D) or Ind (I) (Instr.	irect Ir direct B 4) C	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) c (D)	Price	Transacti (Instr. 3 a	action(s)		"	nstr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
(e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio	ly Di or (I)	D. wnership orm: irect (D) r Indirect) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)			
Employee stock option (right to buy)	\$26.88	01/21/2021		A ⁽¹⁾		212,660		(2)	0:	1/20/2031	Common Stock	212,660	\$0.00	212,660	0	D	

Explanation of Responses:

- 1. This amendment is being filed solely to correct an administrative error in the original Form 4, which reported the number of shares subject to the stock option as 212,600 instead of 212,660.
- 2. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Remarks:

/s/ Elizabeth E. Reed, Attorney-01/28/2021 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.